Anatara Lifesciences Ltd (ASX:ANR) Market Update COVID-19
Anatara Lifesciences Ltd (ASX:ANR) provides an update on the impact to the Company of the COVID-19 pandemic.
Anatara Lifesciences Ltd (ASX:ANR) provides an update on the impact to the Company of the COVID-19 pandemic.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for the Company's lead stem cell platform technology, Progenza, in the U.S.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, Today received a non-refundable milestone payment of 100,000,000 JPY (approx. A$1.6M) from Kyocera Corporation (TYO:6971) as set out in the non-binding Memorandum of Understanding (MOU) signed on 2 March 2020.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it has signed a non-binding MOU with Kyocera Corporation (Kyocera, TYO:6971).
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today released its Half-Year Financial Results and Appendix 4D for the period ended 31 December 2019 (H1 FY20).
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced its Board of Directors has put in place loan facilities totalling $4 million to extend the Company's funding runway to support negotiations to license and commercialise Progenza for knee osteoarthritis (Progenza OA) in Japan.
Anatara Lifesciences Ltd (ASX:ANR) present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the half-year ended 31 December 2019.